Functional, biophysical, and structural bases for antibacterial activity of tigecycline

被引:151
作者
Olson, Matthew W.
Ruzin, Alexey
Feyfant, Eric
Rush, Thomas S., III
O'Connell, John
Bradford, Patricia A.
机构
[1] Wyeth Ayerst Res, Dept Infect Dis, Pearl River, NY 10965 USA
[2] Wyeth Ayerst Res, Dept Chem & Screening Sci, Pearl River, NY 10965 USA
[3] Wyeth Ayerst Res, Dept Computat Chem, Cambridge, MA 02140 USA
[4] Wyeth Ayerst Res, Dept Biol Struct, Cambridge, MA 02140 USA
关键词
D O I
10.1128/AAC.01499-05
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Tigecycline is a novel glycylcycline antibiotic that possesses broad-spectrum activity against many clinically relevant species of bacterial pathogens. The mechanism of action of tigecycline was delineated using functional, biophysical, and molecular modeling experiments in this study. Functional assays showed that tigecycline specifically inhibits bacterial protein synthesis with potency 3- and 20-fold greater than that of minocycline and tetracycline, respectively. Biophysical analyses demonstrated that isolated ribosomes bind tigecycline, minocycline, and tetracycline with dissociation constant values of 10(-8), 10(-7), and > 10(-6) M, respectively. A molecular model of tigecycline bound to the ribosome was generated with the aid of a 3.40-angstrom resolution X-ray diffraction structure of the 30S ribosomal subunit from Thermus thermophilus. This model places tigecycline in the A site of the 30S subunit and involves substantial interactions with residues of H34 of the ribosomal subunit. These interactions were not observed in a model of tetracycline binding. Modeling data were consistent with the biochemical and biophysical data generated in this and other recent studies and suggested that tigecycline binds to bacterial ribosomes in a novel way that allows it to overcome tetracycline resistance due to ribosomal protection.
引用
收藏
页码:2156 / 2166
页数:11
相关论文
共 31 条
[1]   Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA [J].
Bauer, G ;
Berens, C ;
Projan, SJ ;
Hillen, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (04) :592-599
[2]   Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection [J].
Bergeron, J ;
Ammirati, M ;
Danley, D ;
James, L ;
Norcia, M ;
Retsema, J ;
Strick, CA ;
Su, WG ;
Sutcliffe, J ;
Wondrack, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2226-2228
[3]   In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].
Boucher, HW ;
Wennersten, CB ;
Eliopoulos, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229
[4]   In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002 [J].
Bouchillon, SK ;
Hoban, DJ ;
Johnson, BM ;
Stevens, TM ;
Dowzicky, MJ ;
Wu, DH ;
Bradford, PA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 51 (04) :291-295
[5]  
Bradford P. A., 2004, Clinical Microbiology Newsletter, V26, P163, DOI 10.1016/j.clinmicnews.2004.10.001
[6]   The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit [J].
Brodersen, DE ;
Clemons, WM ;
Carter, AP ;
Morgan-Warren, RJ ;
Wimberly, BT ;
Ramakrishnan, V .
CELL, 2000, 103 (07) :1143-1154
[7]   New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors [J].
Chopra, I .
DRUG RESISTANCE UPDATES, 2002, 5 (3-4) :119-125
[8]  
Cull MG, 1995, METHOD ENZYMOL, V262, P22
[9]   Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1 [J].
Dean, CR ;
Visalli, MA ;
Projan, SJ ;
Sum, PE ;
Bradford, PA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :972-978
[10]   THE BINDING OF 6-DEMETHYLCHLORTETRACYCLINE TO 70S, 50S AND 30S RIBOSOMAL PARTICLES - A QUANTITATIVE STUDY BY FLUORESCENCE ANISOTROPY [J].
EPE, B ;
WOOLLEY, P .
EMBO JOURNAL, 1984, 3 (01) :121-126